Although the recent clinical management of patients with HNSCC mainly depends on surgical procedures, chemo- and radiotherapy, and immunotherapy, such as PD1, PDL1, and epidermal growth factor receptor (EGFR) inhibitors [1, 8], in addition to the significant progress recorded in diagnosis and treatment during the past decades, the survival rates for HNSCC patients remains low. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.